3 Clinical Trials to Watch in the First Half of 2022

3 Clinical Trials to Watch in the First Half of 2022

Source: 
Motley Fool
snippet: 
  • Pfizer has a vested interest in Arena's results for etrasimod in treating ulcerative colitis.
  • Roche's upcoming data for Alzheimer's disease candidate gantenerumab could disrupt Biogen's plans.
  • AbbVie's phase 2 results for its cystic fibrosis combo could affect Vertex.